205 related articles for article (PubMed ID: 34581025)
1. Effectiveness of various human papillomavirus vaccination strategies: A community randomized trial in Finland.
Lehtinen M; Apter D; Eriksson T; Harjula K; Hokkanen M; Natunen K; Nieminen P; Paavonen J; Palmroth J; Petäjä T; Pukkala E; Vänskä S; Cheuvart B; Soila M; Bi D; Struyf F
Cancer Med; 2021 Nov; 10(21):7759-7771. PubMed ID: 34581025
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial.
Lehtinen M; Apter D; Baussano I; Eriksson T; Natunen K; Paavonen J; Vänskä S; Bi D; David MP; Datta S; Struyf F; Jenkins D; Pukkala E; Garnett G; Dubin G
Vaccine; 2015 Mar; 33(10):1284-90. PubMed ID: 25593103
[TBL] [Abstract][Full Text] [Related]
3. Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I).
Lehtinen M; Söderlund-Strand A; Vänskä S; Luostarinen T; Eriksson T; Natunen K; Apter D; Baussano I; Harjula K; Hokkanen M; Kuortti M; Palmroth J; Petäjä T; Pukkala E; Rekonen S; Siitari-Mattila M; Surcel HM; Tuomivaara L; Paavonen J; Dillner J; Dubin G; Garnett G
Int J Cancer; 2018 Mar; 142(5):949-958. PubMed ID: 29055031
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of the AS04-adjuvanted HPV-16/18 vaccine in reducing oropharyngeal HPV infections in young females-Results from a community-randomized trial.
Lehtinen M; Apter D; Eriksson T; Harjula K; Hokkanen M; Lehtinen T; Natunen K; Damaso S; Soila M; Bi D; Struyf F
Int J Cancer; 2020 Jul; 147(1):170-174. PubMed ID: 31736068
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial.
Gray P; Kann H; Pimenoff VN; Eriksson T; Luostarinen T; Vänskä S; Surcel HM; Faust H; Dillner J; Lehtinen M
PLoS Med; 2021 Jun; 18(6):e1003588. PubMed ID: 34097688
[TBL] [Abstract][Full Text] [Related]
6. Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years.
Bi D; Apter D; Eriksson T; Hokkanen M; Zima J; Damaso S; Soila M; Dubin G; Lehtinen M; Struyf F
Hum Vaccin Immunother; 2020 Jun; 16(6):1392-1403. PubMed ID: 31829767
[TBL] [Abstract][Full Text] [Related]
7. Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV).
Gray P; Luostarinen T; Vänskä S; Eriksson T; Lagheden C; Man I; Palmroth J; Pimenoff VN; Söderlund-Strand A; Dillner J; Lehtinen M
Int J Cancer; 2019 Aug; 145(3):785-796. PubMed ID: 30719706
[TBL] [Abstract][Full Text] [Related]
8. Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III).
Lehtinen M; Luostarinen T; Vänskä S; Söderlund-Strand A; Eriksson T; Natunen K; Apter D; Baussano I; Harjula K; Hokkanen M; Kuortti M; Palmroth J; Petäjä T; Pukkala E; Rekonen S; Siitari-Mattila M; Surcel HM; Tuomivaara L; Paavonen J; Nieminen P; Dillner J; Dubin G; Garnett G
Int J Cancer; 2018 Nov; 143(9):2299-2310. PubMed ID: 29845626
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?
Bonanni P; Gabutti G; Demarteau N; Boccalini S; La Torre G
BMC Infect Dis; 2015 Sep; 15():377. PubMed ID: 26381489
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II).
Gray P; Palmroth J; Luostarinen T; Apter D; Dubin G; Garnett G; Eriksson T; Natunen K; Merikukka M; Pimenoff V; Söderlund-Strand A; Vänskä S; Paavonen J; Pukkala E; Dillner J; Lehtinen M
Int J Cancer; 2018 Jun; 142(12):2491-2500. PubMed ID: 29377141
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.
Germar MJ; Purugganan C; Bernardino MS; Cuenca B; Chen YC; Li X; Van Kriekinge G; Lee IH
Hum Vaccin Immunother; 2017 May; 13(5):1158-1166. PubMed ID: 28075249
[TBL] [Abstract][Full Text] [Related]
14. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
15. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years.
Schwarz TF; Huang LM; Valencia A; Panzer F; Chiu CH; Decreux A; Poncelet S; Karkada N; Folschweiller N; Lin L; Dubin G; Struyf F
Hum Vaccin Immunother; 2019; 15(7-8):1970-1979. PubMed ID: 31268383
[TBL] [Abstract][Full Text] [Related]
16. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years.
Schwarz TF; Huang LM; Medina DM; Valencia A; Lin TY; Behre U; Catteau G; Thomas F; Descamps D
J Adolesc Health; 2012 Feb; 50(2):187-94. PubMed ID: 22265115
[TBL] [Abstract][Full Text] [Related]
17. Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied.
Vänskä S; Luostarinen T; Baussano I; Apter D; Eriksson T; Natunen K; Nieminen P; Paavonen J; Pimenoff VN; Pukkala E; Söderlund-Strand A; Dubin G; Garnett G; Dillner J; Lehtinen M
J Infect Dis; 2020 Aug; 222(6):948-956. PubMed ID: 32161969
[TBL] [Abstract][Full Text] [Related]
18. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
Kohli M; Lawrence D; Haig J; Anonychuk A; Demarteau N
BMC Public Health; 2012 Oct; 12():872. PubMed ID: 23061913
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore.
Tay SK; Lee BW; Sohn WY; Lee IH; Mathur G; Sanicas M; Van Kriekinge G
Singapore Med J; 2018 Jul; 59(7):370-382. PubMed ID: 28983579
[TBL] [Abstract][Full Text] [Related]
20. Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial.
Lehtinen M; Eriksson T; Apter D; Hokkanen M; Natunen K; Paavonen J; Pukkala E; Angelo MG; Zima J; David MP; Datta S; Bi D; Struyf F; Dubin G
Hum Vaccin Immunother; 2016 Dec; 12(12):3177-3185. PubMed ID: 27841725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
